Published long term Phase I data show evidence of improvements in neurological function sustained out to 24 months and good safety profile.

Read more…

ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer-reviewed scientific journal of further key pre-clinical efficacy data with its human retinal progenitor cells (hRPCs). A Phase I/II clinical trial has recently commenced in the US to evaluate the safety, tolerability and preliminary efficacy of the hRPCs in patients with the inherited blindness-causing disease, retinitis pigmentosa (RP).

Read more..

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2016.

Read more..

Pencoed, UK, 9 June 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has selected glioblastoma multiforme (“GBM”) as the first clinical target for its exosome nanomedicine platform, based on evidence of tumour-inhibiting activity from early pre-clinical studies with the technology.

Read more…

Pencoed, UK, 14 June 2016: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its preliminary results for the year ended 31 March 2016 on Thursday 7 July 2016.

Read More..

Pencoed, UK, 13 June 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with its stroke programme.  The Company has completed patient recruitment in the Phase II clinical trial (PISCES II) of its CTX cell therapy candidate in patients with motor disability as a result of ischaemic stroke.

Read More..

Pencoed, UK, 8 June 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to provide an update on progress with the ongoing US Phase I/II dose escalation study of its human retinal progenitor cell (hRPC) therapy candidate in patients with advanced retinitis pigmentosa (RP).

Read more…

A great-grandfather becomes one of the first in the UK to be treated for a stroke, using stem cells.

Watch video: http://www.bbc.co.uk/news/health-36450628.

Pencoed, UK, 15 March 2016: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that the first patient has been treated with the Company’s cell therapy candidate for the blindness-causing disease retinitis pigmentosa (RP) in a first-in-human US clinical trial.  The procedure, involving a single injection of hRPC cells under the retina, was conducted at Massachusetts Eye and Ear in Boston, a teaching affiliate of Harvard Medical School (HMS) and a world-renowned clinical and research centre for the treatment of eye disease, including retinal degeneration. The patient was discharged from hospital on the same day.

Read More…